CN104027303A - 盐酸吉西他滨水溶液注射液及其制备方法 - Google Patents
盐酸吉西他滨水溶液注射液及其制备方法 Download PDFInfo
- Publication number
- CN104027303A CN104027303A CN201410167699.0A CN201410167699A CN104027303A CN 104027303 A CN104027303 A CN 104027303A CN 201410167699 A CN201410167699 A CN 201410167699A CN 104027303 A CN104027303 A CN 104027303A
- Authority
- CN
- China
- Prior art keywords
- injection
- gemcitabine hydrochloride
- solution
- water
- bottle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title claims abstract description 59
- 229960005144 gemcitabine hydrochloride Drugs 0.000 title claims abstract description 52
- 239000007924 injection Substances 0.000 title claims abstract description 36
- 238000002347 injection Methods 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000243 solution Substances 0.000 title claims description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 239000008215 water for injection Substances 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 19
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 13
- 239000001632 sodium acetate Substances 0.000 claims description 13
- 235000017281 sodium acetate Nutrition 0.000 claims description 13
- 239000003002 pH adjusting agent Substances 0.000 claims description 10
- 229960005277 gemcitabine Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003643 water by type Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000003139 buffering effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 16
- 238000005352 clarification Methods 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 238000011068 loading method Methods 0.000 description 16
- 239000012982 microporous membrane Substances 0.000 description 16
- 230000001954 sterilising effect Effects 0.000 description 16
- 239000003708 ampul Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 8
- 235000019799 monosodium phosphate Nutrition 0.000 description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410167699.0A CN104027303A (zh) | 2014-04-25 | 2014-04-25 | 盐酸吉西他滨水溶液注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410167699.0A CN104027303A (zh) | 2014-04-25 | 2014-04-25 | 盐酸吉西他滨水溶液注射液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104027303A true CN104027303A (zh) | 2014-09-10 |
Family
ID=51458454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410167699.0A Pending CN104027303A (zh) | 2014-04-25 | 2014-04-25 | 盐酸吉西他滨水溶液注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104027303A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112516078A (zh) * | 2020-12-12 | 2021-03-19 | 江苏集萃分子工程研究院有限公司 | 吉西他滨单磷酸酯溶液制剂和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1650883A (zh) * | 2005-01-17 | 2005-08-10 | 黄家章 | 盐酸吉西他滨溶液型注射剂 |
CN101088492A (zh) * | 2006-06-12 | 2007-12-19 | 齐鲁制药(海南)有限公司 | 盐酸吉西他滨稳定的过饱和溶液及其制备方法 |
CN102451156A (zh) * | 2011-07-01 | 2012-05-16 | 江苏豪森药业股份有限公司 | 一种盐酸吉西他滨注射制剂及其制备方法 |
CN102579372A (zh) * | 2012-03-15 | 2012-07-18 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸吉西他滨冻干组合物及其制备方法 |
CN102949337A (zh) * | 2012-11-05 | 2013-03-06 | 江苏豪森药业股份有限公司 | 盐酸吉西他滨注射液及其制备方法 |
-
2014
- 2014-04-25 CN CN201410167699.0A patent/CN104027303A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1650883A (zh) * | 2005-01-17 | 2005-08-10 | 黄家章 | 盐酸吉西他滨溶液型注射剂 |
CN101088492A (zh) * | 2006-06-12 | 2007-12-19 | 齐鲁制药(海南)有限公司 | 盐酸吉西他滨稳定的过饱和溶液及其制备方法 |
CN102451156A (zh) * | 2011-07-01 | 2012-05-16 | 江苏豪森药业股份有限公司 | 一种盐酸吉西他滨注射制剂及其制备方法 |
CN102579372A (zh) * | 2012-03-15 | 2012-07-18 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸吉西他滨冻干组合物及其制备方法 |
CN102949337A (zh) * | 2012-11-05 | 2013-03-06 | 江苏豪森药业股份有限公司 | 盐酸吉西他滨注射液及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112516078A (zh) * | 2020-12-12 | 2021-03-19 | 江苏集萃分子工程研究院有限公司 | 吉西他滨单磷酸酯溶液制剂和应用 |
WO2022121190A1 (zh) * | 2020-12-12 | 2022-06-16 | 江苏集萃分子工程研究院有限公司 | 吉西他滨单磷酸酯溶液制剂和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Impact of residual impurities and contaminants on protein stability | |
US20190040137A1 (en) | Stable antibody formulation | |
EP2521536B1 (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies | |
Garidel et al. | Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations | |
CN101411710B (zh) | 培美曲塞二钠冻干粉针剂及其制备方法 | |
MX2007015960A (es) | Proceso de fabricacion para tigeciclina. | |
EP2946767A1 (en) | Liquid pharmaceutical composition | |
US10300063B2 (en) | Pharmaceutical composition not containing antioxidant and preparation method therefor | |
CN103251565A (zh) | 一种注射用伏立康唑冻干粉针剂及其制备方法 | |
CN102949337B (zh) | 盐酸吉西他滨注射液及其制备方法 | |
CN104027303A (zh) | 盐酸吉西他滨水溶液注射液及其制备方法 | |
AU2013377601B2 (en) | Stable nocathiacin lyophilized powder injection agent | |
CN107789324B (zh) | 一种注射用德拉沙星葡甲胺及其制备方法 | |
CN102475687A (zh) | 一种地西他滨冻干粉针剂 | |
CN108992413B (zh) | 一种培美曲塞二钠冻干粉针剂及其制备方法 | |
Konda et al. | Pharmaceutical development and compatibility studies on cytarabine injection | |
CN104434821B (zh) | 一种注射用甲磺酸加贝酯组合物及其制备方法 | |
CN104173280A (zh) | 一种门冬氨酸鸟氨酸注射液组合物 | |
CN102716096B (zh) | 一种含有头孢替安的药物组合物 | |
CN102526042B (zh) | 稳定的液体药物组合物 | |
CN103599079B (zh) | 注射用洛铂药物组合物及其制备方法 | |
CN103520122B (zh) | 一种注射用布美他尼冻干粉针制剂制备方法 | |
CN110314132B (zh) | 一种门冬氨酸鸟氨酸注射液及其制备方法 | |
Gurumurthaih et al. | Preparation and evaluation of sparfloxacin parenteral dosage form | |
WO2017198224A1 (zh) | 一种瑞马唑仑的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Yi Nuotai Pharmachem Technologies Ltd. Document name: Notification of Publication of the Application for Invention Addressee: Beijing Yi Nuotai Pharmachem Technologies Ltd. Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 100076, Beijing Daxing District old palace Industrial Park, road 10, three Applicant after: Beijing Yi Nuotai Pharmachem Technologies Ltd. Address before: 100176, 22 Old Road Industrial Park, Beijing, Daxing District Applicant before: Beijing Yi Nuotai Pharmachem Technologies Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Beijing Yi Nuotai Pharmachem Technologies Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice |
Addressee: Beijing Yi Nuotai Pharmachem Technologies Ltd. Document name: Notification of before Expiration of Request of Examination as to Substance |
|
DD01 | Delivery of document by public notice | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Yi Nuotai Pharmachem Technologies Ltd. Document name: the First Notification of an Office Action |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Yi Nuotai Pharmachem Technologies Ltd. Document name: Notification that Application Deemed to be Withdrawn |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140910 |
|
WD01 | Invention patent application deemed withdrawn after publication |